1. Home
  2. SCLX vs ITRM Comparison

SCLX vs ITRM Comparison

Compare SCLX & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCLX
  • ITRM
  • Stock Information
  • Founded
  • SCLX 2011
  • ITRM 2015
  • Country
  • SCLX United States
  • ITRM Ireland
  • Employees
  • SCLX N/A
  • ITRM N/A
  • Industry
  • SCLX Biotechnology: Pharmaceutical Preparations
  • ITRM Biotechnology: Pharmaceutical Preparations
  • Sector
  • SCLX Health Care
  • ITRM Health Care
  • Exchange
  • SCLX Nasdaq
  • ITRM Nasdaq
  • Market Cap
  • SCLX 35.7M
  • ITRM 40.0M
  • IPO Year
  • SCLX N/A
  • ITRM 2018
  • Fundamental
  • Price
  • SCLX $13.63
  • ITRM $0.74
  • Analyst Decision
  • SCLX Strong Buy
  • ITRM Strong Buy
  • Analyst Count
  • SCLX 3
  • ITRM 2
  • Target Price
  • SCLX $367.50
  • ITRM $7.00
  • AVG Volume (30 Days)
  • SCLX 225.6K
  • ITRM 807.1K
  • Earning Date
  • SCLX 08-12-2025
  • ITRM 08-05-2025
  • Dividend Yield
  • SCLX N/A
  • ITRM N/A
  • EPS Growth
  • SCLX N/A
  • ITRM N/A
  • EPS
  • SCLX N/A
  • ITRM N/A
  • Revenue
  • SCLX $50,710,000.00
  • ITRM N/A
  • Revenue This Year
  • SCLX $68.30
  • ITRM N/A
  • Revenue Next Year
  • SCLX $124.48
  • ITRM $270.19
  • P/E Ratio
  • SCLX N/A
  • ITRM N/A
  • Revenue Growth
  • SCLX 7.79
  • ITRM N/A
  • 52 Week Low
  • SCLX $3.60
  • ITRM $0.72
  • 52 Week High
  • SCLX $57.75
  • ITRM $3.02
  • Technical
  • Relative Strength Index (RSI)
  • SCLX 65.59
  • ITRM 30.47
  • Support Level
  • SCLX $10.14
  • ITRM $0.72
  • Resistance Level
  • SCLX $17.76
  • ITRM $0.90
  • Average True Range (ATR)
  • SCLX 1.79
  • ITRM 0.07
  • MACD
  • SCLX 0.52
  • ITRM -0.02
  • Stochastic Oscillator
  • SCLX 57.45
  • ITRM 9.56

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

About ITRM Iterum Therapeutics plc

Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

Share on Social Networks: